P033 Validation of GENEActiv actimeters and Cicada Actigraphy Suite in a clinical sleep laboratory setting.

Abstract Introduction The use of Actigraphy in clinical settings is an established approach, with the American Academy of Sleep Medicine (AASM) describing actigraphy as a suggested aid in the diagnosis of multiple sleep disorders such as delayed sleep phase syndrome, narcolepsy and insomnia. Aim The purpose of this study was to review the validity of the GENEActiv accelerometer (Activinsights, Kimbolton, UK) and Cicada Actigraphy Suite (Rick Wassing) in the setting of clinical practice and to optimise settings to align with gold-standard PSG. Methods Actigraphy data of 60 patients using GENEActiv were reviewed against concurrent overnight PSGs. Actiwatch data was compared to PSG metrics of Total Sleep Time (TST), Sleep Efficiency (SE), Sleep Latency (SL) and WASO. Using the open-source GGIR algorithm, the default Cicada 5-Sec epoch was measured against a 30-Sec epoch length comparable with PSG. Results For both epoch durations and following Boneferroni correction (α=0.016), TST and SE were shown to be significantly over-calculated while SL was under-calculated compared to PSG. When comparing epoch lengths WASO times were closer to PSG values when set to 5-second epochs (p>0.016). No other values were shown to be significantly different between the epoch lengths. Conclusion The results demonstrate that when compared to PSG, GENEactiv/Cicada settings markedly overestimate TST and SE and greatly underrepresent SL. While Actigraphy remains a beneficial aid in assisting diagnosis of sleep disorders, clear discrepancies are evident when compared to gold standard PSG. Appropriate clinical correlation should be encouraged when utilising GENEactiv & Cicada actigraphy in a clinical setting.